Sporadic inclusion body myositis;Miositis con cuerpos de inclusión (forma esporádica)

Seminarios de la Fundacion Espanola de Reumatologia

Volumn 13, Issue 1, 2012, Pages 23-30

  Milisenda, José César ^a   Prieto González, Sergio ^a   Grau, Josep Maria ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Inflammatory myopathies; Myopathies; Myositis

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA1A INTERFERON; BIOLOGICAL PRODUCT; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID; TACROLIMUS;

AUTOIMMUNE DISEASE; CLINICAL FEATURE; DELAYED DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; ELECTROMYOGRAPHY; HISTOPATHOLOGY; HUMAN; IDIOPATHIC DISEASE; INCLUSION BODY MYOSITIS; MUSCLE ATROPHY; MUSCLE WEAKNESS; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; SHORT SURVEY; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84858033977     PISSN: 15773566     EISSN: 19883099     Source Type: Journal    
DOI: 10.1016/j.semreu.2011.10.003     Document Type: Short Survey

References (114)

1. Yunis E.J., Samaha F.J. Inclusion body myositis. Lab Invest 1971, 25:240-248.
2. Mammen A.L. Autoimmune myopathies: Autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol 2011, 7:343-354.
3. Dalakas M.C. Review: An update on inflammatory and autoimmune myopathies. Neuropathol Appl Neurobiol 2011, 37:226-242.
4. Diagnostic Criteria in Autoimmune Diseases 2008, Humana Press, Totowa. 1st ed. Y. Shoenfeld, R. Cervera, M.E. Gershwin (Eds.).
5. Prieto S., Grau J.M. The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 2010, 9:330-334.
6. Solorzano G.E., Phillips L.H. Inclusion body myositis: Diagnosis, pathogenesis, and treatment options. Rheum Dis Clin North Am 2011, 37:173-183.
7. Askanas V., Engel W.K. Sporadic inclusion-body myositis: Conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-beta-42 oligomers and phosphorylated tau. Presse Med 2011, 40:219-235.
8. Amato A.A., Barohn R.J. Inclusion body myositis: Old and new concepts. J Neurol Neurosurg Psychiatry 2009, 80:1186-1193.
9. Greenberg S.A. Theories of the pathogenesis of inclusion body myositis. Curr Rheumatol Rep 2010, 12:221-228.
10. Weihl C.C., Pestronk A. Sporadic inclusion body myositis: Possible pathogenesis inferred from biomarkers. Curr Opin Neurol 2010, 23:482-488.
11. Varadhachary A.S., Weihl C.C., Pestronk A. Mitochondrial pathology in immune and inflammatory myopathies. Curr Opin Rheumatol 2010, 22:651-657.
12. Dalakas M.C. Inflammatory muscle diseases: A critical review on pathogenesis and therapies. Curr Opin Pharmacol 2010, 10:346-352.
13. Lloyd T.E. Novel therapeutic approaches for inclusion body myositis. Curr Opin Rheumatol 2010, 22:658-664.
14. Chou S.M. Myxovirus-like structures in a case of human chronic polymyositis. Science 1967, 158:1453-1455.
15. Needham M., Corbett A., Day T., Christiansen F., Fabian V., Mastaglia F.L. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci 2008, 15:1350-1353.
16. Needham M., Mastaglia F.L. Inclusion body myositis: Current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007, 6:620-631.
17. Chahin N., Engel A.G. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008, 70:418-424.
18. Garlepp M.J., Laing B., Zilko P.J., Ollier W., Mastaglia F.L. HLA associations with inclusion body myositis. Clin Exp Immunol 1994, 98:40-45.
19. Greenberg S.A. Inclusion body myositis. Curr Opin Rheumatol 2011, 23:574-578.
20. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. V: Identification and quantitation of T8+ cytotoxic and T8+ suppressor cells. Ann Neurol 1988, 23:493-499.
21. Wiendl H., Hohlfeld R., Kieseier B.C. Immunobiology of muscle: Advances in understanding an immunological microenvironment. Trends Immunol 2005, 26:373-380.
22. Schmidt J., Rakocevic G., Raju R., Dalakas M.C. Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: Significance for CD8+ T cell cytotoxicity. Brain 2004, 127:1182-1190.
23. Schneider C., Gold R., Dalakas M.C., Schmied M., Lassmann H., Toyka K.V., et al. MHC class I-mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: Studies in patients with polymyositis, dermatomyositis, and inclusion body myositis. J Neuropathol Exp Neurol 1996, 55:1205-1209.
24. Greenberg S.A. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007, 69:2008-2019.
25. Pruitt J.N., Showalter C.J., Engel A.G. Sporadic inclusion body myositis: Counts of different types of abnormal fibers. Ann Neurol 1996, 39:139-143.
26. Nagaraju K., Casciola-Rosen L., Rosen A., Thompson C., Loeffler L., Parker T., et al. The inhibition of apoptosis in myositis and in normal muscle cells. J Immunol 2000, 164:5459-5465.
27. Vattemi G., Tonin P., Filosto M., Spagnolo M., Rizzuto N., Tomelleri G. T-cell anti-apoptotic mechanisms in inflammatory myopathies. J Neuroimmunol 2000, 111:146-151.
28. Nagaraju K., Casciola-Rosen L., Lundberg I., Rawat R., Cutting S., Thapliyal R., et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005, 52:1824-1835.
29. Nagaraju K. Role of major histocompatibility complex class I molecules in autoimmune myositis. Curr Opin Rheumatol 2005, 17:725-730.
30. Askanas V., Engel W.K. Molecular pathology and pathogenesis of inclusion-body myositis. Microsc Res Tech 2005, 67:114-120.
31. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984, 16:193-208.
32. Engel A.G., Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984, 16:209-215.
33. Greenberg S.A., Sanoudou D., Haslett J.N., Kohane I.S., Kunkel L.M., Beggs A.H., et al. Molecular profiles of inflammatory myopathies. Neurology 2002, 59:1170-1182.
34. Greenberg S.A., Bradshaw E.M., Pinkus J.L., Pinkus G.S., Burleson T., Due B., et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005, 65:1782-1787.
35. Bradshaw E.M., Orihuela A., McArdel S.L., Salajegheh M., Amato A.A., Hafler D.A., et al. A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 2007, 178:547-556.
36. Figarella-Branger D., Civatte M., Bartoli C., Pellissier J.F. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve 2003, 28:659-682.
37. Cupler E.J., Leon-Monzon M., Miller J., Semino-Mora C., Anderson T.L., Dalakas M.C. Inclusion body myositis in HIV-1 and HTLV-1 infected patients. Brain 1996, 119:1887-1893.
38. Semino-Mora C., Dalakas M.C. Rimmed vacuoles with beta-amyloid and ubiquitinated filamentous deposits in the muscles of patients with long-standing denervation (postpoliomyelitis muscular atrophy): Similarities with inclusion body myositis. Hum Pathol 1998, 29:1128-1133.
39. Griggs R.C., Askanas V., DiMauro S., Engel A., Karpati G., Mendell J.R., et al. Inclusion body myositis and myopathies. Ann Neurol 1995, 38:705-713.
40. Askanas V., Engel W.K. Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. Curr Opin Rheumatol 2007, 19:550-559.
41. Askanas V., Alvarez R.B., Engel W.K. Beta-amyloid precursor epitopes in muscle fibers of inclusion body myositis. Ann Neurol 1993, 34:551-560.
42. Askanas V. New developments in hereditary inclusion body myopathies. Ann Neurol 1997, 41:421-422.
43. Askanas V., Engel W.K. Inclusion-body myositis: A myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology 2006, 66(Suppl 1):S39-S48.
44. Askanas V., Engel W.K. Proposed pathogenetic cascade of inclusion-body myositis: Importance of amyloid-beta, misfolded proteins, predisposing genes, and aging. Curr Opin Rheumatol 2003, 15:737-744.
45. Schmidt J., Barthel K., Wrede A., Salajegheh M., Bahr M., Dalakas M.C. Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008, 131:1228-1240.
46. Lunemann J.D., Schmidt J., Schmid D., Barthel K., Wrede A., Dalakas M.C., et al. Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann Neurol 2007, 61:476-483.
47. Nogalska A., D'Agostino C., Terracciano C., Engel W.K., Askanas V. Impaired autophagy in sporadic inclusion-body myositis and in endoplasmic reticulum stress-provoked cultured human muscle fibers. Am J Pathol 2010, 177:1377-1387.
48. Needham M., Mastaglia F.L. Sporadic inclusion body myositis: a continuing puzzle. Neuromuscul Disord 2008, 18:6-16.
49. DiMauro S., Schon E.A. Mitochondrial respiratory-chain diseases. N Engl J Med 2003, 348:2656-2668.
50. Lodi R., Taylor D.J., Tabrizi S.J., Hilton-Jones D., Squier M.V., Seller A., et al. Normal in vivo skeletal muscle oxidative metabolism in sporadic inclusion body myositis assessed by 31P-magnetic resonance spectroscopy. Brain 1998, 121:2119-2126.
51. Oldfors A., Moslemi A.R., Jonasson L., Ohlsson M., Kollberg G., Lindberg C. Mitochondrial abnormalities in inclusion-body myositis. Neurology 2006, 66:S49-S55.
52. Casademont Pou J., Grau Junyent J.M., Pou Serradell A., Urbano-Marquez A. Myositis with inclusion bodies: a little-known variety of idiopathic inflammatory myopathy. Med Clin (Barc) 1989, 93:121-124.
53. Suomalainen A., Elo J.M., Pietilainen K.H., Hakonen A.H., Sevastianova K., Korpela M., et al. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: A diagnostic study. Lancet Neurol 2011, 10:806-818.
54. Dalakas M.C. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991, 325:1487-1498.
55. Beyenburg S., Zierz S., Jerusalem F. Inclusion body myositis: Clinical and histopathological features of 36 patients. Clin Investig 1993, 71:351-361.
56. Riminton D.S., Chambers S.T., Parkin P.J., Pollock M., Donaldson I.M. Inclusion body myositis presenting solely as dysphagia. Neurology 1993, 43:1241-1243.
57. Felice K.J., North W.A. Inclusion body myositis in Connecticut: Observations in 35 patients during an 8-year period. Medicine (Baltimore) 2001, 80:320-327.
58. Grau JM, Selva-O'Callaghan A, Espígol G, Prieto S, Butjosa M. Inclusion Body Myositis. Presenting forms and outcome [abstract]. 6th International Congress on Autoimmunity; Porto, Portugal; 2008.
59. Schellenberg K.L., Johnston W.S., Kalra S., Resch L., Johnson E.S. Inclusion body myositis masquerading as amyotrophic lateral sclerosis. Can J Neurol Sci 2010, 37:687-691.
60. Prieto-González S., Lazo V., Trallero-Araguás E., Selva-O'Callaghan A., Grau J.M. Myositis and cancer. Idiopathic Inflammatory Myopathies-Recent Developments 2011, In Tech Editors. T.J. Grant (Ed.).
61. Selva-O'Callaghan A., Trallero-Araguas E., Grau-Junyent J.M., Labrador-Horrillo M. Malignancy and myositis: Novel autoantibodies and new insights. Curr Opin Rheumatol 2010, 22:627-632.
62. Jackson C.E., Barohn R.J., Gronseth G., Pandya S., Herbelin L. Inclusion body myositis functional rating scale: A reliable and valid measure of disease severity. Muscle Nerve 2008, 37:473-476.
63. Love L.A., Leff R.L., Fraser D.D., Targoff I.N., Dalakas M., Plotz P.H., et al. A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991, 70:360-374.
64. Hengstman G.J., van Engelen B.G., Badrising U.A., van den Hoogen F.H., van Venrooij W.J. Presence of the anti-Jo-1 autoantibody excludes inclusion body myositis. Ann Neurol 1998, 44:423.
65. Salajegheh M., Lam T., Greenberg S.A. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS One 2011, 6:e20266.
66. Joy J.L., Oh S.J., Baysal A.I. Electrophysiological spectrum of inclusion body myositis. Muscle Nerve 1990, 13:949-951.
67. Eisen A., Berry K., Gibson G. Inclusion body myositis (IBM): Myopathy or neuropathy?. Neurology 1983, 33:1109-1114.
68. Amato A.A., Barohn R.J. Idiopathic inflammatory myopathies. Neurol Clin 1997, 15:615-648.
69. Kuo G.P., Carrino J.A. Skeletal muscle imaging and inflammatory myopathies. Curr Opin Rheumatol 2007, 19:530-535.
70. Cox F.M., Reijnierse M., van Rijswijk C.S., Wintzen A.R., Verschuuren J.J., Badrising U.A. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology (Oxford) 2011, 50:1153-1161.
71. Dion E., Cherin P., Payan C., Fournet J.C., Papo T., Maisonobe T., et al. Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis. J Rheumatol 2002, 29:1897-1906.
72. Lamminen A.E. Magnetic resonance imaging of primary skeletal muscle diseases: Patterns of distribution and severity of involvement. Br J Radiol 1990, 63:946-950.
73. Garcia J. MRI in inflammatory myopathies. Skeletal Radiol 2000, 29:425-438.
74. Dalakas M.C. Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin North Am 2002, 28:779-798.
75. Emslie-Smith A.M., Arahata K., Engel A.G. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989, 20:224-231.
76. Greenberg S.A., Pinkus J.L., Amato A.A. Nuclear membrane proteins are present within rimmed vacuoles in inclusion-body myositis. Muscle Nerve 2006, 34:406-416.
77. Askanas V., Engel W.K., Alvarez R.B. Enhanced detection of Congo-red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer's disease using fluorescence technique. Neurology 1993, 43:1265-1267.
78. Tawil R., Griggs R.C. Inclusion body myositis. Curr Opin Rheumatol 2002, 14:653-657.
79. Lotz B.P., Engel A.G., Nishino H., Stevens J.C., Litchy W.J. Inclusion body myositis. Observations in 40 patients. Brain 1989, 112:727-747.
80. Peng A., Koffman B.M., Malley J.D., Dalakas M.C. Disease progression in sporadic inclusion body myositis: Observations in 78 patients. Neurology 2000, 55:296-298.
81. Griggs R.C. The current status of treatment for inclusion-body myositis. Neurology 2006, 66:S30-S32.
82. Mastaglia F.L., Garlepp M.J., Phillips B.A., Zilko P.J. Inflammatory myopathies: Clinical, diagnostic and therapeutic aspects. Muscle Nerve 2003, 27:407-425.
83. Mastaglia F.L., Zilko P.J. Inflammatory myopathies: How to treat the difficult cases. J Clin Neurosci 2003, 10:99-101.
84. Joffe M.M., Love L.A., Leff R.L., Fraser D.D., Targoff I.N., Hicks J.E., et al. Drug therapy of the idiopathic inflammatory myopathies: Predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 1993, 94:379-387.
85. Leff R.L., Miller F.W., Hicks J., Fraser D.D., Plotz P.H. The treatment of inclusion body myositis: A retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine (Baltimore) 1993, 72:225-235.
86. Barohn R.J., Amato A.A., Sahenk Z., Kissel J.T., Mendell J.R. Inclusion body myositis: Explanation for poor response to immunosuppressive therapy. Neurology 1995, 45:1302-1304.
87. Sayers M.E., Chou S.M., Calabrese L.H. Inclusion body myositis: Analysis of 32 cases. J Rheumatol 1992, 19:1385-1389.
88. Yood R.A., Smith T.W. Inclusion body myositis and systemic lupus erythematosus. J Rheumatol 1985, 12:568-570.
89. Cohen M.R., Sulaiman A.R., Garancis J.C., Wortmann R.L. Clinical heterogeneity and treatment response in inclusion body myositis. Arthritis Rheum 1989, 32:734-740.
90. Badrising U.A., Maat-Schieman M.L., Ferrari M.D., Zwinderman A.H., Wessels J.A., Breedveld F.C., et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002, 51:369-372.
91. Hopkinson N.D., Hunt C., Powell R.J., Lowe J. Inclusion body myositis: An underdiagnosed condition?. Ann Rheum Dis 1993, 52:147-151.
92. Mowzoon N., Sussman A., Bradley W.G. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001, 185:119-122.
93. Quartuccio L., De Marchi G., Scott C.A., Ferraccioli G., Beltrami C.A., De Vita S. Treatment of inclusion body myositis with cyclosporin-A or tacrolimus: Successful long-term management in patients with earlier active disease and concomitant autoimmune features. Clin Exp Rheumatol 2007, 25:246-251.
94. Lynn S.J., Sawyers S.M., Moller P.W., O'Donnell J.L., Chapman P.T. Adult-onset inflammatory myopathy: North Canterbury experience 1989-2001. Intern Med J 2005, 35:170-173.
95. Dalakas M.C. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 1997, 126:721-730.
96. Dalakas M.C., Koffman B., Fujii M., Spector S., Sivakumar K., Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001, 56:323-327.
97. Walter M.C., Lochmuller H., Toepfer M., Schlotter B., Reilich P., Schroder M., et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: A double-blind, placebo-controlled study. J Neurol 2000, 247:22-28.
98. Soueidan S.A., Dalakas M.C. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 1993, 43:876-879.
99. Amato A.A., Barohn R.J., Jackson C.E., Pappert E.J., Sahenk Z., Kissel J.T. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1994, 44:1516-1518.
100. Cherin P., Pelletier S., Teixeira A., Laforet P., Simon A., Herson S., et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 2002, 58:326.
101. Dalakas M.C., Rakocevic G., Schmidt J., Salajegheh M., McElroy B., Harris-Love M.O., et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009, 132:1536-1544.
102. Lindberg C., Trysberg E., Tarkowski A., Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 2003, 22:260-262.
103. Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis. Neurology 2001, 13:1566-1570.
104. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology 2004; 63: 718-20.
105. Darrow D.H., Hoffman H.T., Barnes G.J., Wiley C.A. Management of dysphagia in inclusion body myositis. Arch Otolaryngol Head Neck Surg 1992, 118:313-317.
106. Arnardottir S., Alexanderson H., Lundberg I.E., Borg K. Sporadic inclusion body myositis: Pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med 2003, 35:31-35.
107. Viitanen J.V., Heikkila S. Functional changes in patients with spondylarthropathy. A controlled trial of the effects of short-term rehabilitation and 3-year follow-up. Rheumatol Int 2001, 20:211-214.
108. Rutkove S.B., Parker R.A., Nardin R.A., Connolly C.E., Felice K.J., Raynor E.M. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 2002, 58:1081-1087.
109. Rodino-Klapac L.R., Haidet A.M., Kota J., Handy C., Kaspar B.K., Mendell J.R. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve 2009, 39:283-296.
110. Mann H.F., Vencovský J. Clinical trials roundup in idiopathic inflammatory myopathies. Curr Opin Rheumatol 2011, 23:605-611.
111. Nogalska A., D'Agostino C., Terracciano C., Engel W.K., Askanas V. Impaired autophagy in sporadic inclusion-body myositis and in endoplasmic reticulum stress-provoked cultured human muscle fibers. Am J Pathol 2010, 177:1377-1387.
112. Caccamo A., Majumder S., Deng J.J., Bai Y., Thornton F.B., Oddo S. Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. J Biol Chem 2009, 284:27416-27424.
113. Askanas V., Engel W.K. Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains. Acta Neuropathol 2008, 116:583-595.
114. Sancricca C., Mora M., Ricci E., Tonali P.A., Mantegazza R., Mirabella M. Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis. Neurol Sci 2011, 32:841-847.